Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases

Cancer Research

Volumn 58, Issue 17, 1998, Pages 3918-3925

  Xiang, Rong ^a   Lode, Holger N ^a   Dreier, Torsten ^a   Gillies, Stephen D ^b   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Lexigen Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; IMMUNOMODULATION; IMMUNOREACTIVITY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0032170538     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Talmage, D. W., Woolnough, J. A., Hemmingsen, H., Lopez, O., and Lafferty, K. J. Activation of cytotoxic T cells, nonstimulating tumor cells, and spleen cell factor(s). Proc. Natl. Acad. Sci. USA, 77: 4610-4614, 1977.
2. Fisher, R. I., Coltman, C. A., Doroshow, J. H., Rayner, A. A., Hawkins, M. J., Mier, J. W., Wiernik, P., McMannis, J. D., and Weiss, O. R. Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells: a Phase II clinical trial. Ann. Intern. Med., 108: 518-523, 1988.
3. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, R., Seipp, L. A., Einhorn, J. H., and White, D. W. Treatment of 283 consecutive patients with metastastic melanoma or renal cell cancer using high-dose bolus interleukin-2. J. Am. Med. Assoc., 271: 945-946, 1994.
4. Forni, G., Giovarelli, M., Santoni, A., Modesti, A., and Forni, M. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J. Immunol., 87: 4033-4041, 1987.
5. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995.
6. Dranoff, G., and Mulligan, R. C. Gene transfer as cancer treatment. Adv. Immunol., 58: 417-454, 1995.
7. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172: 1217-1224, 1990.
8. Fearon, E. G., Pardoll, E. M., Itaya, T., Golumbek, P., Levitsky, H. Y., Simons, T. A., Karasuyama, H., Vogelstein, B., and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell, 60: 397-403, 1990.
9. Zatloukal, K. A., Schneeberger, M., Berger, W., Schmidt, F., Koszik, R., Kutil, M., Cotton, E., Wagner, M., Buschle, G., Maass, E., Payer, S. G., and Birnstiel, M. L. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J. Immunol., 154: 3406-3419, 1995.
10. Maass, G., Schmidt, W., Berger, M., Schilcher, F., Koszik, F., Schneeberger, A., Stingl, G., Birnstiel, M. L., and Schweighoffer, T. Priming of tumor specific T cells in the draining lymph nodes after immunization with IL-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA, 92: 5540-5544, 1995.
11. Sitkovsky, M. V., and Paul, W. Global or directed exocytosis? Nature (Lond.), 332: 306-307, 1988.
12. Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S. D., and Reisfeld, R. A. Targeted interleukin-2 therapy of spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. (Bethesda), 89: 1586-1594, 1997.
13. Becker, J. C., Pancook, J. D., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med., 183: 2361-2366, 1996.
14. Xiang, R., Lode, H. N., Dolman, C. S., Dreier, T., Varki, N. M., Qian, X., Lo, K-M., Lan, Y., Super, M., Gillies, S. D., and Reisfeld, R. A. Elimination of established murine carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res., 57: 4948-4955, 1997.
15. Varki, N. M., Reisfeld, R. A., and Walker, L. E. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res., 44: 681-685, 1984.
16. Perez, M.S., and Walker, L. E. Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J. Immunol., 142: 3662-3667, 1989.
17. Szala, S., Froelich, M., Scollon, M., Kasai, Y., Steplewski, Z., Koprowski, H., and Linnenbach, A. J. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc. Natl. Acad. Sci. USA, 87: 3542-3546, 1990.
18. Gillies, S. D., Lan, Y., Wesolowski, J. S., Qian, X., Reisfeld, R. A., Holden, S., Super, M., and Lo, K-M. Antibody-IL-2 fusion proteins are effective in SCID mouse models of prostate and colon cancer metastases. J. Immunol., 160: 6195-6203, 1998.
19. Dreier, T., Lode, H. N., Xiang, R., Dolman, C. S., Reisfeld, R. A., and Kang, A. S. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities. Bioconj. Chem., 9: 482-489, 1998.
20. Lanzavecchia, A. Mechanism of antigen uptake for presentation. Curr. Opin. Immunol., 8: 348-352, 1966.
21. + T cells, Immunol. Rev., 117: 213-234, 1990.
22. Sprent, J. Antigen-presenting cells: professionals and amateurs. Curr. Biol., 95: 1095-1097, 1995.
23. Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A., Kühlcke, K., Ohashi, P. S., Hengartner, H., and Zinkernagel, R. M. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science (Washington DC), 268: 1343-1347, 1995.
24. Testi, R., D'Ambrosio, D., DeMaria, R., and Santoni, A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol. Today, 15: 479-483, 1994.
25. Testi, R., Phillips, J. H., and Lanier, L. L. T cell activation via Leu-23 (CD69). J. Immunol., 143: 1123-1128, 1989.
26. Beverley, P. C. L. Generation of T-cell memory. Curr. Opin. Immunol., 8: 327-330, 1996.
27. H compartment. Immunol. Rev., 150: 5-21, 1996.
28. Sprent, J., Tough, D. F., and Sun, S. Factor controlling the turnover of T memory cells, Immunol. Rev., 156: 79-85, 1997.
29. Tough, D. F., and Sprent, J. Viruses and T cell turnover: evidence of bystander proliferation. Immunol. Rev., 150: 129-142, 1996.
30. Zinkernagel, R. M., Bachmann, M. F., Kündig, T. M., Oehen, S., Pirchet, H., and Hengartner, H. On immunological memory. Annu. Rev. Immunol., 14: 333-367, 1996.
31. Kündig, T. M., Bachmann, M. F., Ohashi, P. S., Pircher, H., Hengartner, H., and Zinkemagel, R. M. On T cell memory: arguments for antigen dependence. Immunol. Rev., 150: 63-90, 1996.
32. DiRosa, F., and Matzinger, P. Long-lasting CD8 T cells memory in the absence of CD4 T cells or B cells. J. Exp. Med., 176: 2153-2163, 1996.
33. Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest., 98: 2801-2804, 1996.